02/26/21
|
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41 st Annual Health Care Conference , Wednesday, March 3 , at 2:40 p.m. ET . To access the live webcast of bluebird bio’s
|
|
02/24/21
|
First pivotal study of BCMA-directed CAR T cell therapy in triple-class exposed relapsed and refractory multiple myeloma Biologics License Application (BLA) for ide-cel was accepted by FDA for Priority Review, with a target action date of March 27, 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.
|
|
02/23/21
|
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 23, 2021-- bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress. “For over ten years, bluebird bio has been pioneering
|
|
02/22/21
|
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 22, 2021-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 10 th Annual SVB Leerink Global Healthcare Conference , Thursday, February 25 , at 12:00 p.m. ET .
|
|
02/16/21
|
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 16, 2021-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that the company has placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary suspension due to a reported
|
|
01/11/21
|
Severe Genetic Disease business will remain the focus of bluebird bio, Inc.; separation expected to result in two independent, publicly traded companies by year-end 2021 Separation designed to unlock value through improved operational execution, organizational focus, tailored capital allocation,
|
|